PuSH - Publication Server of Helmholtz Zentrum München: Complementary antisense oligonucleotide treatment and precision sodium channel modulation for early onset SCN2A developmental and epileptic encephalopathy: Emergency use case in a preterm infant with refractory status epilepticus (P10-11.009).

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Frizzo, S.* ; Wagner, M. ; Zaddach, M.* ; Nussbaum, C.* ; Berecki, G.* ; Flemmer, A.* ; Heinen, F.* ; Spar, B.* ; Staudt, M.* ; Tacke, M.* ; Wolff, M.* ; Fazeli, W.* ; Petrou, S.* ; Souza, M.* ; Borggraefe, I.*

Complementary antisense oligonucleotide treatment and precision sodium channel modulation for early onset SCN2A developmental and epileptic encephalopathy: Emergency use case in a preterm infant with refractory status epilepticus (P10-11.009).

Neurology 106:2271 (2026)

DOI

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

ObjectiveThis is a case report of the first complementary emergency use of the antisense oligonucleotide (ASO), elsunersen, and the precision sodium channel modulator, relutrigine, in an infant with severe early onset SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) and refractory status epilepticus (SE).BackgroundEarly onset SCN2A-DEE is a rare, fatal disorder characterized by developmental delay or regression, frequent, treatment-resistant seizures, typically beginning within days of birth. Clinical studies with a gapmer SCN2A ASO show significant seizure reduction, amongst other benefits. However, persistent network hyperexcitability in a developmentally altered brain may remain. Adjunctive precision sodium channel modulation could further stabilize excitability and enhance clinical outcomes. Elsunersen, an intrathecally-administered ASO in development for early onset SCN2A-DEE, has shown well-tolerated, significant, sustained seizure reduction. Relutrigine, a sodium channel functional state modulator, has demonstrated robust, sustained seizure reduction in a diverse DEE population.Design/MethodsA preterm infant (29+4 weeks gestation; birthweight 1400g) diagnosed prenatally with a pathogenic SCN2A variant presented with life-threatening SE and only partial effect of high-dose sodium channel blockers (SCBs). Following confirmation of gain-of-function status, elsunersen was initiated at 7 weeks, with 26 monthly doses administered to date (182.5mg total). Relutrigine was introduced two years later (0.5mg/kg daily) with the objective of enhancing clinical outcomes.ResultsElsunersen in combination with best standard-of-care ASMs (mainly SCBs) was well-tolerated. Early dosing led to SE cessation and revealed a temporal association with seizure reduction. Seizure frequency remained stable, maintained after tapering phenytoin at 14 months, with no further neurodevelopmental worsening. As early as three weeks after relutrigine commencement, parents and nursing staff reported moderate-to-significant improvement including fewer, less severe seizures, with no new safety findings. Continued improvement in clinical status permitted a previously unattainable reduction in carbamazepine dosage.ConclusionsFirst-in-patient findings point to elsunersen’s potential for enhancement via adjunctive precision sodium channel modulation addressing residual network hyperexcitability.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Keywords Status Epilepticus ; Sodium Channel ; Refractory (planetary Science) ; Epilepsy ; Sodium Channel Blocker ; Refractory Period

ISSN (print) / ISBN 0028-3878

e-ISSN 1526-632X

Journal Neurology

Quellenangaben Volume: 106, Issue: 11_Supplement_1, Article Number: 2271

Publisher Lippincott Williams & Wilkins

Reviewing status Peer reviewed

Institute(s) Institute of Neurogenomics (ING)